Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. (Q39371422)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612285%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

0 references

1 reference

title

Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612285%20AND%20SRC:MED&resulttype=core&format=json

polycystic ovary syndrome

22 March 2020

main subject

1 reference

1 reference

metabolic dysfunction–associated steatotic liver disease

1 reference

non-alcoholic fatty liver

inferred from title

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612285%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Claudia A Couto

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612285%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Fernando M. Reis

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612285%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

author name string

L C Faria

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612285%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

T C M Guimarães

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612285%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

G V Moreira

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612285%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

A L Cândido

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612285%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

publication date

13 June 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612285%20AND%20SRC:MED&resulttype=core&format=json

Journal of Endocrinological Investigation

22 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612285%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612285%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612285%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

page(s)

1279-1288

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612285%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40618-017-0708-9

22 March 2020

exact match

0 references

cites work

Review of treatment options for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

The epidemiology of nonalcoholic fatty liver disease: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Hepatic manifestations of women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Cross talk of the immune system in the adipose tissue and the liver in non-alcoholic steatohepatitis: Pathology and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Roles of Chemokines and Chemokine Receptors in Obesity-Associated Insulin Resistance and Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Inflammatory links between obesity and metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Fat: a matter of disturbance for the immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Imaging of hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

CLINICAL PRACTICE. Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Genetic, hormonal and metabolic aspects of PCOS: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Prevalence of hepatic steatosis in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Non-alcoholic fatty liver disease in women with polycystic ovary syndrome - clinical and metabolic aspects and lipoprotein lipase gene polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Obesity and PCOS: implications for diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-017-0708-9

Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS)

21 January 2018

1 reference

12 December 2020

Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease

1 reference

12 December 2020

Ultrasonography in the diagnosis of benign diffuse parenchymal liver diseases: a prospective study.

1 reference

12 December 2020

In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls.

1 reference

12 December 2020

Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis

1 reference

12 December 2020

Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment

1 reference

12 December 2020

Effect of obesity on nonalcoholic fatty liver disease in Chinese women with polycystic ovary syndrome

1 reference

12 December 2020

Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case-control study

1 reference

12 December 2020

Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens.

1 reference

12 December 2020

Nonalcoholic fatty liver disease in women with polycystic ovary syndrome

1 reference

12 December 2020

10.1007/S40618-017-0708-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612285%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

1 reference